Yarrow Bioscience, Inc. (YARW) SEC Filings & Earnings Calls

Dilution risk from equity offering.

“5,769,231 shares + 865,384 greenshoe = 6,634,615 total shares issued.”

Clinical-stage company with no approved products

“We are a clinical-stage biotechnology company with a limited operating history as a combined company on which to assess our business; we have not completed any clinical trials, and have no products approved for commercial sale.” · word for word

Substantial additional capital required

“We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or discontinue development of YB-101 or our future commercialization efforts.” · word for word

Dependence on YB-101 success

“Our future success is substantially dependent on our ability to timely obtain regulatory approval for, and then successfully commercialize, YB-101.” · word for word

Reliance on GenSci license and third-party manufacturers

“We currently solely rely on GenSci to provide biological development and manufacturing services. If there is any disruption in such supply arrangement, including any adverse events affecting our sole supplier, or if we experience delays or difficulties in transferring, or are unable to successfully transfer, our manufacturing processes, it could have a negat”

Intellectual property risk – no issued patents

“We do not currently own or in-license any issued patents, but have filed one U.S. provisional patent application related to methods of treating GD with YB-101.” · word for word

Extreme dilution risk: pre-funded warrants outstanding (25.9M) far exceed common shares (2.7M), implying massive potential dilution upon exercise.

“Pre-Funded Warrants to purchase 25,914,530 shares of Common Stock outstanding vs 2,669,788 shares of Common Stock outstanding.”

Low exercise price ($0.0001) means warrants are essentially deep in-the-money, likely to be exercised.

“Pre-Funded Warrants to purchase an aggregate of 133,290 shares of Common Stock at an exercise price of $0.0001 per share” · word for word

Integration risk from merger; potential dilution from authorized share increase and reverse stock split.

“Authorized share increase and reverse stock split implemented; new stock incentive plan and ESPP adopted.”

Reverse stock split (1-for-50) and special dividend indicate financial distress and restructuring.

“reverse stock split of VYNE's common stock at a ratio of 1-for-50... aggregate Cash Dividend of $17.3 million”

Massive dilution: fully diluted shares (33.6M) are ~12x basic shares (2.7M) post-merger.

“approximately 2.7 million shares, or approximately 33.6 million shares on a fully-diluted basis, or approximately 28.6 million shares excluding shares underlying equity plans and awards.” · word for word

Dividend is contingent on merger closing; if merger fails, dividend may not be paid.

“Payment of the Cash Dividend is conditioned upon the closing of the Merger.” · word for word

Going concern / merger failure

“If the Merger is not completed, the Company may pursue other strategic alternatives, including financing opportunities, or liquidation.” · word for word

Clinical hold on VYN202

“In April 2025, the U.S. Food and Drug Administration (FDA) verbally placed a clinical hold on the Company’s Phase 1b trial evaluating VYN202 in subjects with moderate-to-severe plaque psoriasis following an observation of testicular toxicity in dogs from a non-clinical toxicology study of VYN202.” · word for word

Failed Phase 2b for repibresib

“In July 2025, the Company announced that the trial did not meet its primary endpoint of the proportion of subjects achieving an improvement in Facial Vitiligo Area Scoring Index of at least 50% from baseline ('F-VASI50') at week 24 compared to vehicle.” · word for word

Limited financing capacity under baby shelf rules

“As of the filing of this Quarterly Report, we are subject to the general instructions of Form S-3 known as the 'baby shelf rules.' Under these rules, the amount of funds we can raise through primary public offerings of securities in any 12-month period using our registration statement on Form S-3 is limited to one-third of the aggregate market value of the s”

Capital constraint risk

“We will need substantial additional funding to pursue our business objectives if the Merger is not completed.” · word for word

Clinical trial risk

“we are evaluating a gel formulation of repibresib in our Phase 2b trial rather than an ointment, which was used in our completed Phase 1b trial. Such modifications carry the risk that they will not achieve these intended objectives” · word for word

Milestone payment uncertainty

“Journey does not have any diligence obligations to achieve any such net sales milestones, and we can provide no assurance that such milestones will ever be met.” · word for word

Baby shelf limitation

“SEC regulations limit the amount that companies with a public float of less than $75 million may raise during any 12-month period pursuant to a shelf registration statement on Form S-3” · word for word

Lead candidate failure

“the Company’s Phase 2b results in its lead product candidate repibresib gel failed to meet its primary endpoint.” · word for word

Liquidity risk

“The Company... was not able to obtain capital needed to provide sufficient liquidity for the funding of all aspects of its strategic plan.”

Clinical trial failure

“In July 2025, we announced that the trial did not meet its primary endpoint of the proportion of subjects achieving an improvement in Facial Vitiligo Area Scoring Index of at least 50% from baseline ("F-VASI50") at week 24 compared to vehicle.” · word for word

Regulatory hold

“In April 2025, the U.S. Food and Drug Administration ("FDA") verbally placed a clinical hold on our Phase 1b trial evaluating VYN202 in subjects with moderate-to-severe plaque psoriasis following an observation of testicular toxicity in dogs from a non-clinical toxicology study of VYN202.” · word for word

Going concern / capital need

“Our future viability is dependent on our ability to successfully execute our business strategy and develop our product candidates and raise additional capital to finance operations.” · word for word

VYN202 partial clinical hold for male subjects due to testicular toxicity in dogs; requires 12-week toxicology study to resume.

“FDA placed clinical hold on Phase 1b trial of VYN202 following observation of testicular toxicity in dogs; partial hold for male subjects.”

Repibresib gel Phase 2b trial failed primary endpoint; trial terminated.

“The trial did not meet the primary or secondary endpoint of F-VASI50 and F-VASI75.” · word for word

Strategic review outcome uncertain; no guarantee of value-creating transaction.

“There can be no assurance that the process will result in any such transaction.” · word for word